B. Nordenskjöld

B. Nordenskjöld, L. Brudin, M. Sundquist, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Common cancer-related symptoms among GP patients. Opportunistic screening in primary health care.

A. Håkansson, B. Nordenskjöld, L. Carlsson, 2001, Scandinavian journal of primary health care.

Estrogen Receptor-alpha Phosphorylation at Serine 305 , Nuclear p 21-Activated Kinase 1 Expression , and Response to Tamoxifen in Postmenopausal Breast Cancer

L. Skoog, O. Stål, B. Nordenskjöld, 2010 .

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

M. Piccart, M. Gnant, A. Goldhirsch, 2015, European journal of cancer.

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

P. Malmström, O. Stål, J. Carstensen, 2011, British Journal of Cancer.

17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.

L. Rydén, O. Stål, B. Nordenskjöld, 2010, European journal of cancer.

DNA content, malignancy grading and prognosis in T1 and T2 oral cavity carcinomas.

B. Nordenskjöld, U. Brunk, J. Olofsson, 1987, British Journal of Cancer.

Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas.

B. Nordenskjöld, L. Vavruch, B. Frånlund, 1998, Neuro-Chirurgie.

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study.

B. Nordenskjöld, E. Holmberg, P. Karlsson, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study.

B. Nordenskjöld, E. Holmberg, P. Karlsson, 2015 .

Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer

Elin Karlsson, Olle Stål, L. Skoog, 2011, Breast Cancer Research and Treatment.

Amplification of HSD17B1 and ERBB2 in primary breast cancer

K. Kirschner, L. Skoog, O. Stål, 2003, Oncogene.

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

L. Skoog, O. Stål, B. Nordenskjöld, 2007, Oncogene.

Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients

L. Skoog, O. Stål, B. Nordenskjöld, 2009, Clinical Cancer Research.

Relationship between nuclear DNA distribution and estrogen receptors in human mammary carcinomas.

B. Ljung, T. Caspersson, G. Auer, 1980, Analytical and quantitative cytology.

Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel.

J. Gustafsson, B. Nordenskjöld, O. Wrange, 1978, Analytical biochemistry.

Estradiol receptor analysis in human breast cancer tissue by isoelectric focusing in polyacrylamide gel.

J. Gustafsson, B. Nordenskjöld, C. Silfverswärd, 1978, Cancer research.

Progestin-receptor analysis in human breast cancer cytosol by isoelectric focusing in slabs of polyacrylamide gel.

J. Gustafsson, L. Skoog, B. Nordenskjöld, 1981, Journal of steroid biochemistry.

Akt kinases in breast cancer and the results of adjuvant therapy

Olle Stål, L. Skoog, O. Stål, 2003, Breast Cancer Research.

Clinical potential of the mTOR targets S 6 K 1 and S 6 K 2 in breast cancer

L. Skoog, O. Stål, B. Nordenskjöld, 2011 .

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

L. Skoog, O. Stål, B. Nordenskjöld, 2005, Breast Cancer Research and Treatment.

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

L. Skoog, O. Stål, B. Nordenskjöld, 2007, Clinical Cancer Research.

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer

O. Stål, B. Nordenskjöld, T. Fornander, 2018, Journal of Cancer Research and Clinical Oncology.

Hypoxia, Snail and incomplete epithelial–mesenchymal transition in breast cancer

B. Nordenskjöld, G. Landberg, K. Lundgren, 2009, British Journal of Cancer.

Apoptosis in rectal carcinoma

O. Stål, B. Nordenskjöld, Xiao-Feng Sun, 2001, Cancer.

Effects of methotrexate on deoxyribonucleotide pools and nucleic acid synthesis in human osteosarcoma cells.

L. Skoog, B. Nordenskjöld, T. Hägerström, 1976, European journal of cancer.

S‐phase fraction after gating on epithelial cells predicts recurrence in node‐negative breast cancer

S. Wingren, S. Sullivan, B. Nordenskjöld, 1994, International journal of cancer.

Swedish Cancer Society Radiation Therapy Research Investigation

Eva Forssell-Aronsson, A. Brahme, B. Zackrisson, 2002, Acta oncologica.

Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

J. Bergh, H. Mouridsen, B. Nordenskjöld, 2008, Acta oncologica.

Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas.

H. Zhang, X. Sun, J. Carstensen, 1996, European journal of cancer.

Glutathione S‐transferase T1 and M1 genotypes in normal mucosa, transitional mucosa and colorectal adenocarcinoma

Hong Zhang, J. Carstensen, B. Nordenskjöld, 1999, International journal of cancer.

K-ras mutations in colorectal adenocarcinomas and neighbouring transitional mucosa.

H. Zhang, P. Söderkvist, X. Sun, 1998, European journal of cancer.

A comparison of static cytofluorometry and flow cytometry for the estimation of ploidy and DNA replication in human breast cancer

L. Skoog, O. Stål, B. Nordenskjöld, 1986, Breast Cancer Research and Treatment.

Estrogen and progestin receptor analysis in human breast cancer by isoelectric focusing in slabs of polyacrylamide gel.

J. Gustafsson, B. Nordenskjöld, O. Wrange, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients

S. Wingren, O. Stål, J. Carstensen, 2009 .

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

R. Gelber, M. Gnant, A. Goldhirsch, 2018, International journal of radiation oncology, biology, physics.

A novel p53 germline alteration identified in a late onset breast cancer kindred.

Å. Borg, O. Johannsson, H. Olsson, 1996, Oncogene.

Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial.

J. Bergh, P. Malmström, J. Carstensen, 2005, Journal of the National Cancer Institute.

Deoxyribonucleoside-triphosphate pools and DNA synthesis in synchronized hamster cells.

B. Nordenskjöld, K. Skoog, K. G. Bjursell, 1973, European journal of biochemistry.

Effects of hydroxyurea and 1-beta-D-arabinofuranosyl-cytosine on deoxyribonucleotide pools in mouse embryo cells.

B. Nordenskjöld, L. Skoog, B. Nordenskjöld, 1971, European journal of biochemistry.

Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.

M. Fernö, L. Rydén, O. Stål, 2019, European journal of cancer.

A comparison of three different methods for the determination of estrogen receptors in human breast cancer.

B. Nordenskjöld, B. Frånlund, B. Boeryd, 1988, American journal of clinical pathology.

Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma.

B. Nordenskjöld, A. de Schryver, G. P. Forshell, 1975, European journal of cancer.

Interactions between Chemotherapy, Endocrine Therapy and Radiation

B. Zackrisson, B. Nordenskjöld, B. Glimelius, 2002, Acta oncologica.

Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin

J. Bergh, H. Mouridsen, M. Andersson, 1999 .

Heat shock protein 72/73 in relation to cytoplasmic p53 expression and prognosis in colorectal adenocarcinomas

H. Zhang, Hong Zhang, X. Sun, 1997, International journal of cancer.

Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma

H. Zhang, S. Wingren, O. Stål, 1992, The Lancet.

Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer

O. Stål, B. Nordenskjöld, C. Gunnarsson, 2008, Breast Cancer Research and Treatment.

Expression of c-erbB-2 and p53 in colorectal adenocarcinoma.

X. Sun, J. Carstensen, B. Nordenskjöld, 1995, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

L. Esserman, J. Hartman, C. Benz, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma.

H. Zhang, S. Wingren, O. Stål, 1991, European journal of cancer.

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients

M. Fernö, P. Bendahl, L. Rydén, 2022, NPJ breast cancer.

Estrogen Receptor Assay in Human Mammary Carcinoma with the Synthetic Estrogen 11β-Methoxy-17α-ethinyl-1,3,5(10)-estratriene-3,17β-diol (R 2858)

J. Gustafsson, B. Nordenskjöld, C. Silfverswärd, 1978 .

Biochemical markers as indicators of prognosis in acute nonlymphocytic leukemia (ANLL).

B. Nordenskjöld, A. Ost, R. Hast, 1980, Advances in enzyme regulation.

Oestrogen receptors and peripheral serum levels of oestradiol-17beta in patients with mammary carcinoma.

J. Gustafsson, B. Nordenskjöld, O. Wrange, 1978, European journal of cancer.

c‐erbB‐2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma

H. Zhang, O. Stål, X. Sun, 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.

B. Nordenskjöld, E. Varenhorst, B. Kågedal, 1988, Acta oncologica.

Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.

S. Wingren, O. Stål, B. Nordenskjöld, 1994, British Journal of Cancer.

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen

P. Malmström, O. Stål, J. Carstensen, 2017, Acta oncologica.

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.

A. Andersson, L. Skoog, S. Wingren, 1994, British Journal of Cancer.

In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients

S. Wingren, B. Nordenskjöld, P. Wegman, 2008, Breast Cancer Research and Treatment.

Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator.

S. Wingren, O. Stål, B. Nordenskjöld, 1989, Gynecologic oncology.

Relationships of DNA ploidy, S‐phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening

O. Stål, L. Ferraud, J. Carstensen, 1992, International journal of cancer.

Deoxyribonucleotide pools and deoxyribonucleic acid synthesis in cultured mouse embryo cells.

B. Nordenskjöld, P. Reichard, N. Brown, 1970, The Journal of biological chemistry.

Thymidine phosphate pools and DNA synthesis after polyoma infection of mouse embryo cells.

B. Nordenskjöld, P. Reichard, U. Lindberg, 1969, Cancer research.

S-phase determination of immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence

S. Wingren, O. Stål, J. Carstensen, 1994, Breast Cancer Research and Treatment.

IP6K2 predicts favorable clinical outcome of primary breast cancer

O. Stål, B. Nordenskjöld, L. Lindström, 2021, Molecular and clinical oncology.

Ras p21 expression in relation to histopathological variables and prognosis in colorectal adenocarcinoma.

H. Zhang, S. Wingren, O. Stål, 1991, Acta oncologica.

Cellular DNA pattern, S-phase frequency and survival in papillary thyroid cancer.

J. Jónasson, J. Hrafnkelsson, K. Ólafsdóttir, 1988, Acta oncologica.

Adenoid cystic carcinoma: DNA as a prognostic indicator

J. Carstensen, B. Nordenskjöld, G. Franzén, 1991, The Laryngoscope.

Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute non-lymphocytic leukaemia.

B. Andersson, A. Öst, B. Nordenskjöld, 1981, British medical journal.

Deoxyribonucleotide Pools and Deoxyribonucleic Acid Synthesis in Mouse Embryo Cells Infected with Three Classes of Polyoma Virus Particles

B. Nordenskjöld, U. Lindberg, L. Skoog, 1970, Journal of virology.

Increase in viral antigen in individual polyoma‐virus‐infected mouse kidney cells as studied by quantitative immunofluorescence

B. Nordenskjöld, A. Levin, D. Killander, 1973, International journal of cancer.

p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer.

O. Stål, X. Sun, B. Nordenskjöld, 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

L. Esserman, K. Czene, K. Hoadley, 2018, Journal of the National Cancer Institute.

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

O. Stål, J. Carstensen, B. Nordenskjöld, 1992, British Journal of Cancer.

Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer.

L. Skoog, O. Stål, B. Nordenskjöld, 2006, International journal of oncology.

Estrogen receptor concentrations in 269 cases of histologically classified human breast cancer

J. Gustafsson, B. Nordenskjöld, C. Silfverswärd, 1980, Cancer.

Soft tissue sarcoma and occupational exposures

O. Axelson, M. Fredrikson, B. Nordenskjöld, 1990, Cancer.

Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.

S. Wingren, O. Stål, B. Nordenskjöld, 2013, Oncology reports.

Prognostic significance of terminal transferase activity and glucocorticoid receptor levels in acute myeloid leukemia.

B. Nordenskjöld, P. Biberfeld, B. Christensson, 1984, British Journal of Cancer.

Relationship of DNA ploidy and S-phase fraction to survival after first recurrence of breast cancer.

L. Skoog, S. Wingren, O. Stål, 1994, Acta oncologica.

MEMBRANE IMMUNOFLUORESCENCE ON CULTURED INDICATOR CELLS AS A MEASURE OF VIRUS PRODUCTION BY MOUSE L CELLS AND BY TWO MOLONEY LYMPHOMA SUBLINES DIFFERING IN IMMUNOSENSITIVITY *

E. Fenyö, E. Klein, B. Nordenskjöld, 1971, Annals of the New York Academy of Sciences.

Hypoxia inducible factor‐1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response

K. Jirström, L. Rydén, B. Nordenskjöld, 2006, International journal of cancer.

Intratumoral variation of cytoplasmic and nuclear estrogen receptor concentrations in human mammary carcinoma.

L. Skoog, B. Nordenskjöld, C. Silfverswärd, 1980, European journal of cancer.

Steriod hormone receptors and endocrine management of mammary carcinoma.

B. Nordenskjöld, 2009, Acta medica Scandinavica.

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

R. Gelber, D. Larsimont, M. Buyse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival bene fi t for sequential doxorubicin – docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer — 8-year results of the Breast International Group 02-98 phase III trial †

D. Larsimont, M. Buyse, G. Viale, 2013 .

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

R. Gelber, M. Buyse, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Effects of repeated mammographic screening on breast cancer stage distribution. Results from a randomised study of 92 934 women in a Swedish county.

L. Baldetorp, O. Gröntoft, G. Fagerberg, 1985, Acta radiologica. Oncology.

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer

Å. Borg, K. Holm, B. Nordenskjöld, 2008, Breast Cancer Research.

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

M. Fernö, K. Jirström, L. Rydén, 2005, Journal of Clinical Pathology.

Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.

Mårten Fernö, Sten Thorstenson, Lisa Rydén, 2005, European journal of cancer.

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer

O. Stål, B. Nordenskjöld, T. Fornander, 2015, Breast Cancer Research and Treatment.

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.

L. Skoog, O. Stål, J. Carstensen, 2013, European journal of cancer.

Long-term effects of mammography screening: updated overview of the Swedish randomised trials

Ingvar Andersson, L. Nyström, B. Nordenskjöld, 2002, The Lancet.

Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern

M. Fernö, K. Jirström, P. Berglund, 2007, Journal of Clinical Pathology.

Postprint Exploring the two-gene ratio in breast cancer – independent roles for HOXB 13 and IL 17 BR in prediction of clinical outcome

M. Fernö, S. Gruvberger-Saal, S. Wingren, 2008 .

Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome

M. Fernö, S. Gruvberger-Saal, S. Wingren, 2007, Breast Cancer Research and Treatment.

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up

P. Malmström, O. Stål, J. Carstensen, 2013, Breast Cancer Research and Treatment.

A comparative study of DNA cytometry methods for benign and malignant thyroid tissue.

J. Hrafnkelsson, S. Wingren, B. Nordenskjöld, 1988, American journal of clinical pathology.

Adenoid cystic carcinoma: Significance of DNA ploidy

B. Nordenskjöld, M. Tytor, R. Grenko, 1995, Head & neck.

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

L. Miller, O. Stål, B. Nordenskjöld, 2015, Clinical Cancer Research.

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer

M. Fernö, D. Sgroi, L. Skoog, 2014, Breast Cancer Research and Treatment.

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

M. Fernö, P. Bendahl, L. Rydén, 2020, Breast cancer research : BCR.

p53 expression and the result of adjuvant therapy of breast cancer.

L. Skoog, S. Wingren, O. Stål, 1995, Acta oncologica.

Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer.

L. Skoog, O. Stål, B. Nordenskjöld, 2007, International journal of radiation oncology, biology, physics.

Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer.

L. Skoog, S. Wingren, O. Stål, 1989, European journal of cancer & clinical oncology.

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.

F. Spyratos, O. Stål, B. Nordenskjöld, 2010, European journal of cancer.

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

R. Salunga, M. Erlander, D. Sgroi, 2011, British Journal of Cancer.

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information

M. Fernö, P. Bendahl, L. Rydén, 2008, Breast Cancer Research and Treatment.

Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.

L. Skoog, O. Stål, B. Nordenskjöld, 2009, International journal of oncology.

The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.

L. Skoog, B. Nordenskjöld, H. Johansson, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial

O. Gröntoft, G. Fagerberg, O. Stål, 1989, Breast Cancer Research and Treatment.

Cytometric characterization and clinical course of breast cancer diagnosed in a population‐based screening program

O. Gröntoft, G. Fagerberg, O. Stål, 1989, Cancer.

A comparison between flow cytometric assessment of S-phase fraction and Nottingham histologic grade as prognostic instruments in breast cancer

O. Stål, B. Nordenskjöld, L. Brudin, 2000, Breast Cancer Research and Treatment.

S-phase fraction is a prognostic factor in stage I breast carcinoma.

L. Skoog, S. Wingren, O. Stål, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interrelations between cellular DNA content, S-phase fraction, hormone receptor status and age in primary breast cancer. A series of 1,342 consecutively detected tumors. South-East Sweden Breast Cancer Group.

O. Stål, L. Ferraud, J. Carstensen, 1992, Acta oncologica.

Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma.

L. Skoog, O. Stål, B. Nordenskjöld, 1986, Breast cancer research and treatment.

DNA distribution, cytosol estrogen receptors and axillary nodes as prognostic predictors in breast carcinoma.

L. Skoog, B. Nordenskjöld, A. Wallgren, 1985, Acta radiologica. Oncology.

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

L. Esserman, C. Benz, C. Yau, 2017, Breast Cancer Research and Treatment.

Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.

J. Carstensen, B. Nordenskjöld, P. Persson, 1992, Gynecologic oncology.

Applying the Nottingham Prognostic Index to a Swedish breast cancer population

Sten Thorstenson, Lars Brudin, Marie Sundquist, 2004, Breast Cancer Research and Treatment.

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

M. Fernö, K. Jirström, P. Bendahl, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy

B. Viták, R. Gustavsson, C. Dabrosin, 2009, Acta oncologica.

The Stockholm trial on adjuvant tamoxifen in early breast cancer

L. Skoog, B. Nordenskjöld, H. Johansson, 1987, Breast Cancer Research and Treatment.

3H-thymidine incorporation into mammary carcinoma cells obtained by needle aspiration before and during endocrine therapy.

B. Nordenskjöld, J. Zajicek, T. Löwhagen, 1976, Acta cytologica.

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

O. Stål, J. Carstensen, B. Nordenskjöld, 2020, Molecular and clinical oncology.

Anti-oestrogen therapy of advanced mammary carcinoma.

H. Westerberg, B. Nordenskjöld, A. D. Schryver, 1976, Acta radiologica: therapy, physics, biology.

Proliferating cell nuclear antigen (PCNA) in relation to ras, c‐erbB‐2, p53, clinico‐pathological variables and prognosis in colorectal adenocarcinoma

Hong Zhang, O. Stål, J. Carstensen, 1996, International journal of cancer.

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.

M. Fernö, P. Malmström, Å. Borg, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer.

H. Zhang, O. Stål, X. Sun, 2001, International journal of radiation oncology, biology, physics.

Expression of COX-2 and steroid converting enzymes in breast cancer.

L. Skoog, O. Stål, L. Ferraud, 2006, Oncology reports.

Assay of polyoma virus infectivity by haemagglutinin induction.

B. Nordenskjöld, 1969, The Journal of general virology.

DNA ploidy and S-phase in recurrent astrocytomas: a retrospective study by flow cytometry of deparaffinized specimens

J. Carstensen, B. Nordenskjöld, L. Vavruch, 1996, Journal of Neuro-Oncology.

Prognostic value of flow cytometry and correlation to some conventional prognostic factors: a retrospective study of archival specimens of 134 astrocytomas.

J. Carstensen, B. Nordenskjöld, L. Vavruch, 1996, Journal of neurosurgery.

DNA index and S-phase in primary brain tumors. A comparison between fresh and deparaffinized specimens studied by flow cytometry.

S. Wingren, J. Carstensen, B. Nordenskjöld, 1994, Journal of neurosurgery.

Comparison of static and flow cytofluorometry for estimation of DNA index and S-phase fraction in fresh and paraffin-embedded breast carcinoma tissue.

S. Wingren, O. Stål, B. Nordenskjöld, 1988, Acta oncologica.

Cellular deoxyribonucleotide triphosphate pools levels and DNA synthesis.

B. Nordenskjöld, K. Skoog, K. G. Bjursell, 1974, Advances in enzyme regulation.

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

R. Gelber, W. McCaskill-Stevens, P. Francis, 2009, Breast Cancer Research and Treatment.

Interval cancers and cancers in non-attenders in the Ostergötland Mammographic Screening Programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence.

B. Viták, O. Stål, B. Nordenskjöld, 1997, European journal of cancer.

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

J. Bergh, L. Skoog, O. Stål, 2011, Breast Cancer Research and Treatment.

Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy

Carsten Peterson, Mårten Fernö, Morten Krogh, 2008, Breast Cancer Research.

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

L. Skoog, O. Stål, B. Nordenskjöld, 2010, Breast Cancer Research.

Incidence and prognosis in early onset breast cancer.

S. Wingren, B. Nordenskjöld, L. Brudin, 2002, Breast.

Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma.

H. Zhang, X. Sun, B. Nordenskjöld, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: Correlation and relative prognostic influence

O. Gröntoft, G. Fagerberg, O. Stål, 1990, Breast Cancer Research and Treatment.

Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy.

L. Skoog, B. Nordenskjöld, A. Wallgren, 1987, Acta oncologica.

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy

L. Esserman, C. Benz, C. Yau, 2021, JAMA network open.

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

L. Esserman, K. Hoadley, C. Benz, 2017, JAMA oncology.

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

D. Sgroi, L. Skoog, O. Stål, 2013, Breast Cancer Research.

Survival after treatment for breast cancer in a geographically defined population

B. Nordenskjöld, B Nordenskjöld, M. Dufmats, 2004, The British journal of surgery.

Measurement of DNA synthesis by 3H-thymidine incorporation into needle aspirates from human tumors.

A. Zetterberg, B. Nordenskjöld, T. Löwhagen, 1974, Acta Cytologica.

3H-thymidine autoradiography and cytophotometric analysis of needle aspirates from human tumours during radiation therapy, endocrine therapy and chemotherapy.

B. Nordenskjöld, D. Killander, C. Klintenberg, 1985, Acta radiologica. Oncology.

Measurements of DNA synthesis and estrogen receptor in needle aspirates as powerful methods in the management of mammary carcinoma.

B. Ljung, J. Gustafsson, L. Skoog, 1981, Advances in enzyme regulation.

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

L. Esserman, H. Ditzel, O. Stål, 2021, npj Breast Cancer.

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

L. Esserman, H. Ditzel, J. Andersen, 2021, npj Breast Cancer.

Estrogen receptor level and other factors in early recurrence of breast cancer

H. Westerberg, B. Nordenskjöld, C. Silfverswärd, 1980, International journal of cancer.

Cytophotometric estimation of cell proliferation in breast cancer. Correlation to the clinical course during long-term follow-up.

B. Nordin, B. Stenkvist, O. Stål, 1989, Acta oncologica.

Steroid receptor levels in breast cancer. Relationships with age and menopausal status.

L. Skoog, B. Nordenskjöld, N. Wilking, 1989, Acta oncologica.

Effect of adjuvant therapy in primary breast cancer in relation to the estrogen receptor level.

L. Skoog, B. Nordenskjöld, U. Glas, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients

M. Fernö, P. Bendahl, L. Rydén, 2022, npj Breast Cancer.

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

B. Nordenskjöld, E. Holmberg, P. Karlsson, 2021, Breast.

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

D. Sgroi, L. Skoog, O. Stål, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A pilot study on risk factors and p53 gene expression in colorectal cancer.

O. Axelson, M. Fredrikson, P. Söderkvist, 1996, British Journal of Cancer.

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer

L. Skoog, O. Stål, B. Nordenskjöld, 2012, PloS one.

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

L. Esserman, C. Benz, C. Yau, 2022, International journal of cancer.

Use of formalin fixed, paraffin embedded tumours for estimation of cellular DNA content and S-phase fraction by static cytofluorometry.

O. Stål, B. Nordenskjöld, T. Hatschek, 1985, Acta radiologica. Oncology.

DNA-measurements on formalin-fixed, paraffin-embedded squamous cell carcinomas from different ENT-regions.

B. Nordenskjöld, J. Olofsson, B. Risberg, 1986, Pathology, research and practice.

Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma

Hong Zhang, O. Stål, J. Carstensen, 2005, Virchows Archiv A.

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.

M. Gnant, G. Viale, M. Piccart-Gebhart, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Tamoxifen Treatment in Operable Breast Cancer. Should the Treatment Continue for Many Years

L. Skoog, B. Nordenskjöld, U. Glas, 1984 .

Swedish Cancer Society radiation therapy research investigation.

Eva Forssell-Aronsson, B. Zackrisson, B. Stenerlöw, 2002, Acta oncologica.

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype

O. Stål, B. Nordenskjöld, T. Fornander, 2019, Journal of Cancer Research and Clinical Oncology.

RAB 6 C is an independent prognostic factor of estrogen receptor ‐ positive / progesterone receptor ‐ negative breast cancer

O. Stål, J. Carstensen, B. Nordenskjöld, 2019 .

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.

L. Esserman, K. Czene, K. Hoadley, 2019, JAMA oncology.

Isoelectric focusing of estradiol receptor protein from human mammary carcinoma - a comparison to sucrose gradient analysis.

J. Gustafsson, B. Nordenskjöld, C. Silfverswärd, 1976, European journal of cancer.

Heterogeneity of salivary gland tumors studied by flow cytometry

P. Lundquist, S. Wingren, B. Nordenskjöld, 1993, Head & neck.

Prognostic significance of DNA ploidy in mucoepidermoid carcinoma

P. Lundquist, B. Nordenskjöld, H. Hellquist, 2004, European Archives of Oto-Rhino-Laryngology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

P. Malmström, L. Rydén, O. Stål, 2023, Breast.

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.

M. Fernö, P. Bendahl, L. Rydén, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma

J. Carstensen, B. Nordenskjöld, Xiao-Feng Sun, 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer

L. Skoog, O. Stål, B. Nordenskjöld, 2012, PLoS ONE.

Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial.

G. Viale, P. Francis, R. Jakesz, 2009 .

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

O. Stål, J. Carstensen, B. Nordenskjöld, 2019, Oncology letters.

Interrelations of clinicopathologic variables and their prognostic value in colorectal adenocarcinoma

O. Stål, J. Carstensen, B. Nordenskjöld, 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.

A. Hackshaw, M. Baum, B. Nordenskjöld, 2006, European journal of cancer.

Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.

S. Wingren, O. Stål, B. Nordenskjöld, 2013, Oncology reports.

Steroid Receptor Levels and Prophylactic Endocrine Therapy of Mammary Carcinoma

L. Skoog, B. Nordenskjöld, A. Wallgren, 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.

Estrogen receptor analysis on fine needle aspirates from human breast carcinoma.

B. Nordenskjöld, C. Silfverswärd, A. Wallgren, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial

M. Fernö, P. Bendahl, L. Rydén, 2023, Breast Cancer Research.

Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.

M. Fernö, P. Bendahl, L. Rydén, 2024, Acta oncologica.